Peak is a PK/PD construct describing the modeled time and magnitude at which plasma concentration reaches its highest point within a specified concentration–time trajectory. Its geometry emerges from the interaction of absorption extent, absorption rate, systemic input, distribution, metabolic turnover and clearance rather than from a single isolated parameter. Absorption extent determines how much drug enters systemic circulation, while absorption rate and gastric or intestinal handling shape the temporal profile of that input. The distribution–absorption transition can modify the observed plasma concentration curve as drug moves between central and peripheral compartments. Metabolic turnover and clearance then influence how rapidly concentration begins to decline relative to continuing systemic input. The resulting peak concentration and peak time form the PK component of peak characterization. PD coupling adds a second layer because concentration is mapped through a concentration–effect relationship governed by parameters such as potency, slope and maximal modeled effect. Thus, peak is a mechanistic descriptor of exposure and concentration–effect geometry, not a clinical outcome. The broader PK/PD framework is described in the overview.
Sildenafil and avanafil can be represented through the same general PK/PD framework while producing different modeled peak geometries when their absorption, distribution and metabolic parameters differ. Absorption extent affects the amount entering systemic circulation, whereas absorption rate controls how rapidly that input accumulates in the central compartment. The shape of systemic input therefore influences both the timing and magnitude of the concentration maximum. Distribution can interact with absorption during the rising phase, altering how quickly administered drug appears in plasma relative to movement into peripheral compartments. Metabolic turnover and clearance also contribute because ongoing elimination can oppose accumulation before or around the concentration maximum. These mechanisms can create differences in the width, height or timing of modeled concentration peaks without treating peak as an independent biological event. Peak geometry should also be distinguished from onset and duration: onset concerns the early trajectory and concentration–effect initiation, while duration concerns persistence and decline. The relationships among these temporal regions can be examined through onset comparison, peak effect comparison and duration comparison. Absorption and distribution mechanisms are further developed in absorption differences and distribution differences.
Peak variability can arise from both PK parameters controlling concentration formation and PD parameters controlling concentration–effect translation. PK variability includes differences in absorption extent, absorption rate, gastric emptying, intestinal availability, distribution volume or rate, metabolic turnover and clearance. Each parameter can alter the concentration–time trajectory and therefore shift peak magnitude, peak timing or peak shape. PD variability operates downstream of concentration and can alter how a given plasma concentration is mapped onto modeled effect. Potency changes the concentration scale of the relationship, slope changes its curvature or steepness, and pathway sensitivity changes how concentration interacts with the modeled signaling system. Consequently, two modeled profiles with similar PK peaks can produce different effect-peak geometries, while different PK profiles can converge on similar modeled effect levels under particular parameter combinations. This separation is important because PK variability describes differences in exposure formation, whereas PD variability describes differences in concentration–effect coupling. The PK component is examined in pk variability, while the concentration–effect component is addressed in pd variability. Together, these layers define peak as an integrated PK/PD construct rather than a single measurable mechanism.
Absorption extent describes the fraction or amount of administered drug that becomes systemically available, while absorption rate describes how quickly that input enters systemic circulation. Dissolution, gastric emptying and intestinal availability can modify the temporal structure of this process, producing different rates and shapes of systemic input. A rapid input geometry can generate a steep concentration rise, whereas a more distributed input can broaden the ascending portion of the concentration–time curve. The distribution–absorption transition adds another layer because drug entering the central compartment can simultaneously redistribute into peripheral compartments. Distribution rate and volume therefore influence how much of the absorbed drug remains represented in plasma during peak formation. The observed peak emerges when systemic input, distribution and elimination processes collectively produce the maximum of the concentration trajectory. Absorption extent primarily influences exposure magnitude, while absorption rate strongly influences peak timing and the steepness of the rising phase. These interacting determinants form the principal PK basis for peak formation and are examined further through absorption differences.
For sildenafil and avanafil, mechanistic comparison of peak geometry focuses on how compound-specific PK parameters interact rather than treating peak as a standalone property. Differences in absorption extent can alter the total systemic amount available to form the concentration trajectory, while differences in absorption rate can modify the slope and timing of the ascending phase. Distribution then competes with continued systemic input, influencing the fraction of drug represented in the central concentration compartment as the peak develops. A faster redistribution process can change central concentration geometry even when systemic input is similar, while a different distribution volume can alter concentration magnitude for a given amount present. Metabolic turnover and clearance contribute by removing drug during the same interval in which absorption and distribution are shaping concentration. Consequently, peak height and peak timing reflect the combined balance of input, distribution and elimination rather than absorption alone. These relationships connect peak formation with distribution differences and metabolism differences.
| Peak Domain | Sildenafil | Avanafil | Link |
|---|---|---|---|
| Absorption Extent | Determines magnitude of systemic input. | Determines magnitude of systemic input. | absorption differences |
| Absorption Rate | Shapes early concentration rise. | Shapes early concentration rise. | absorption differences |
| Systemic Input Geometry | Defines early exposure formation. | Defines early exposure formation. | onset comparison |
| Distribution–Absorption Transition | Influences peak timing and magnitude. | Influences peak timing and magnitude. | distribution differences |
| Metabolic Turnover | Shapes early decline after peak. | Shapes early decline after peak. | metabolism differences |
The PK peak establishes a concentration trajectory that is subsequently interpreted through the concentration–effect relationship. Potency determines the concentration scale at which a modeled effect relationship changes, while slope determines how sharply modeled effect changes as concentration rises. A higher concentration peak therefore does not automatically represent a proportionally higher modeled effect when the concentration–effect relationship is nonlinear or approaches its upper asymptote. Maximal modeled effect defines the limiting response parameter within the selected PD model, while pathway sensitivity determines how the modeled signaling system responds to changes in PDE5 inhibition. Sildenafil and avanafil both act through PDE5 inhibition within the NO–cGMP signaling framework, so their peak-related PD interpretation concerns concentration–effect coupling rather than direct generation of NO or activation of soluble guanylate cyclase. The interaction between concentration peak and downstream signaling parameters can therefore be separated into PK formation and PD translation. This distinction is central to interpreting mechanistic peak behavior alongside the no → cGMP cascade differences.
PK and PD variability can alter modeled peak behavior through distinct parameter pathways. PK variability changes the concentration–time trajectory by modifying absorption extent, absorption rate, distribution, metabolic turnover or clearance. Such changes can shift peak magnitude or timing before any concentration–effect relationship is applied. PD variability acts on the subsequent mapping from concentration to modeled effect. Differences in potency can shift the concentration scale, differences in slope can change the steepness of the effect curve, and pathway sensitivity can modify the concentration region in which the modeled system changes most strongly. Consequently, PD variability can alter the modeled effect associated with a PK peak even when the underlying concentration maximum is unchanged. Conversely, PK variability can change concentration peak geometry while PD parameters remain fixed. Separating these layers prevents concentration peak and effect peak from being treated as identical constructs. The distinction between exposure variability and concentration–effect variability is developed through pk variability and pd variability.
| PD Domain | Peak Interaction Determinant | Link |
|---|---|---|
| Potency | Determines concentration scale for effect. | pd variability |
| Slope | Determines rate of effect change with concentration. | pd variability |
| Pathway Sensitivity | Determines modeled activation threshold. | no → cGMP cascade differences |
| Maximal Modeled Effect | Upper limit of modeled response. | duration comparison |
Mechanistic peak differences arise from the combined geometry of absorption, distribution, metabolism and clearance. Absorption extent influences the amount entering systemic circulation, while absorption rate determines how quickly systemic input contributes to the rising concentration trajectory. Distribution affects the relationship between drug entering the central compartment and movement into peripheral compartments. Metabolic turnover and clearance remove drug during the same interval, opposing accumulation and influencing when the concentration maximum occurs. The resulting peak is therefore a system-level property of the concentration–time model rather than a direct property of any single parameter. Downstream PD parameters can further distinguish concentration peak from modeled effect peak. Potency, slope, maximal modeled effect and pathway sensitivity determine how the concentration trajectory is translated into the concentration–effect relationship. Differences between sildenafil and avanafil can therefore be represented as differences in parameter combinations and their resulting PK/PD geometry, without treating peak as a clinical outcome or performance measure.
Absorption extent determines the quantity of drug available for systemic exposure, whereas absorption rate determines the temporal pattern of that exposure. Together they define systemic input geometry, including the steepness, duration and overall shape of the ascending concentration trajectory. Gastric emptying, dissolution and intestinal availability can influence the timing and completeness of systemic entry, while distribution can simultaneously remove drug from the central compartment into peripheral compartments. Peak formation occurs when the combined rate of systemic input, distribution and elimination produces the maximum of the concentration–time curve. A larger systemic input can increase concentration magnitude, whereas a faster input can shift the concentration maximum toward an earlier portion of the trajectory. Clearance and metabolic turnover can counterbalance absorption before the maximum is reached, changing both peak height and timing. Thus, peak geometry reflects the dynamic balance among input, distribution and elimination rather than absorption extent alone.
PK variability changes the concentration–time profile itself. Differences in absorption extent or rate, distribution parameters, metabolic turnover and clearance can shift peak concentration, peak timing or the shape of the surrounding trajectory. PD variability acts on a separate layer by changing how a given concentration is converted into modeled effect. Potency modifies the concentration scale of the effect relationship, slope modifies its steepness, and pathway sensitivity changes the modeled response to concentration changes. Therefore, two profiles can have similar PK peak concentrations but different modeled effect peaks when PD parameters differ. Conversely, different PK peaks can produce similar modeled effects under particular concentration–effect parameter combinations. This distinction is important because peak concentration is a PK quantity, whereas peak modeled effect is generated after the concentration trajectory is passed through a PD model. Peak variability should therefore be interpreted as the combined result of exposure formation and concentration–effect coupling rather than as a single source of variation.
Peak, onset and duration describe different regions or properties of the same modeled PK/PD trajectory. Onset concerns the early rising phase and the point at which the concentration trajectory enters a defined concentration–effect region. Peak concerns the maximum concentration or corresponding maximum within a specified modeled trajectory. Duration concerns persistence and decline after exposure has entered the relevant effect region. These constructs can interact but are not interchangeable. A change in absorption rate can alter onset and peak timing without determining the complete duration profile. Similarly, clearance and metabolic turnover can alter post-peak decline without necessarily determining the initial rising phase. Distribution can influence both the ascending and descending regions through compartmental movement. PD parameters add another distinction because concentration peak and effect peak need not coincide when the concentration–effect relationship is nonlinear. Separating these temporal constructs allows peak geometry to be analyzed mechanistically without treating it as a clinical outcome or as a proxy for real-world performance.